Pazopanib

Pazopanib Reactions 1680, p275 - 2 Dec 2017 Malaise and aspartate aminotransferase elevation: case report An adult man in his 20’s [exact age not stated] developed malaise and aspartate aminotransferase elevation during treatment with pazopanib [time to reaction onsets and outcomes not stated]. The man presented in March 2016 at the age of 23 years with a tongue swelling and was diagnosed with alveolar soft part sarcoma in May 2016. He underwent a complete excision of the mass in June. In September, he developed a recurrence of the alveolar soft part sarcoma and was started on combination therapy with doxorubicin and ifosfamide. However, the mass continued to grow rapidly and the regimen was withheld, and he was started on monotherapy with oral pazopanib 800 mg/day in October. Subsequently, he developed grade 1 malaise and aspartate aminotransferase elevation of 56 U/L. Author comment: "Pazopanib was well tolerated and the patient experienced no severe adverse events other than Grade 1 malaise, aspartate aminotransferase elevation (56 U/l) according to the Common Terminology Criteria for Adverse Events". Yoshihiro T, et al. Lingual alveolar soft part sarcoma responsive to pazopanib: A case report. Medicine 96: e8470, No. 44, Nov 2017. Available from: URL: http:// doi.org/10.1097/MD.0000000000008470 - Japan 803285342 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Pazopanib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/pazopanib-zokVeEHiW0
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39206-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p275 - 2 Dec 2017 Malaise and aspartate aminotransferase elevation: case report An adult man in his 20’s [exact age not stated] developed malaise and aspartate aminotransferase elevation during treatment with pazopanib [time to reaction onsets and outcomes not stated]. The man presented in March 2016 at the age of 23 years with a tongue swelling and was diagnosed with alveolar soft part sarcoma in May 2016. He underwent a complete excision of the mass in June. In September, he developed a recurrence of the alveolar soft part sarcoma and was started on combination therapy with doxorubicin and ifosfamide. However, the mass continued to grow rapidly and the regimen was withheld, and he was started on monotherapy with oral pazopanib 800 mg/day in October. Subsequently, he developed grade 1 malaise and aspartate aminotransferase elevation of 56 U/L. Author comment: "Pazopanib was well tolerated and the patient experienced no severe adverse events other than Grade 1 malaise, aspartate aminotransferase elevation (56 U/l) according to the Common Terminology Criteria for Adverse Events". Yoshihiro T, et al. Lingual alveolar soft part sarcoma responsive to pazopanib: A case report. Medicine 96: e8470, No. 44, Nov 2017. Available from: URL: http:// doi.org/10.1097/MD.0000000000008470 - Japan 803285342 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off